|
Video: What is a Stock Split?
|
|
Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with unmet medical need. Co. has commercially launched LUPKYNIS in the U.S. for the treatment of adult patients with active LN, and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. According to our Aurinia Pharmaceuticals stock split history records, Aurinia Pharmaceuticals has had 0 splits. | |
|
Aurinia Pharmaceuticals (AUPH) has 0 splits in our Aurinia Pharmaceuticals stock split history database.
Looking at the Aurinia Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aurinia Pharmaceuticals shares, starting with a $10,000 purchase of AUPH, presented on a split-history-adjusted basis factoring in the complete Aurinia Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/04/2014 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$3.73 |
|
End price/share: |
$4.91 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
31.64% |
|
Average Annual Total Return: |
2.89% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$13,164.14 |
|
Years: |
9.65 |
|
|
|
|
|